EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE

Gerard J Criner iD, Jorge M Mallea, Muhanned Abu-Hijleh, Ashutosh Sachdeva, Ravi Kalhan iD, Christopher A Hergott, Donald R Lazarus, Richard A Mularski, Karel Calero, Michael F Reed, Stephanie Nsiah-Dosu, David Himes und 11 weitere

Annals of the American Thoracic Society · 2024

DOI: 10.1513/annalsats.202306-520oc ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the American Thoracic Society, 2024. Verfasst von Gerard J Criner und 22 weiteren Autor:innen. Beteiligte Einrichtung: Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Pulmonary Emphysema, Emphysema, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Olympus Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Follow-up of patients with emphysema treated with endobronchial valves is limited to 3–12 months after treatment in prior reports. To date, no comparative data exist between treatment and control subjects with a longer follow-up.

Objectives

To assess the durability of the Spiration Valve System (SVS) in patients with severe heterogeneous emphysema over a 24-month period.

Methods

EMPROVE, a multicenter randomized controlled trial, presents a rigorous comparison between treatment and control groups for up to 24 months. Lung function, respiratory symptoms, and quality-of-life (QOL) measures were assessed.

Results

A significant improvement in forced expiratory volume in 1 second was maintained at 24 months in the SVS treatment group versus the control group. Similarly, significant improvements were maintained in several QOL measures, including the St. George’s Respiratory Questionnaire and the COPD Assessment Test. Patients in the SVS treatment group experienced significantly less dyspnea than those in the control group, as indicated by the modified Medical Research Council dyspnea scale score. Adverse events at 24 months did not significantly differ between the SVS treatment and control groups. Acute chronic obstructive pulmonary disease exacerbation rates in the SVS treatment and control groups were 13.7% (14 of 102) and 15.6% (7 of 45), respectively. Pneumothorax rates in the SVS treatment and control groups were 1.0% (1 of 102) and 0.0% (0 of 45), respectively.

Conclusions

SVS treatment resulted in statistically significant and clinically meaningful durable improvements in lung function, respiratory symptoms, and QOL, as well as a statistically significant reduction in dyspnea, for at least 24 months while maintaining an acceptable safety profile. Clinical trial registered with www.clinicaltrials.gov (NCT01812447).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmphysemaEmphysemaPulmonary Disease, Chronic ObstructiveHumansQuality of LifeFollow-Up StudiesBronchoscopyTreatment OutcomeForced Expiratory VolumeDyspnea

Stichwörter der Autor:innen

air trappingchronic obstructive pulmonary diseasedyspneaendobronchial valveshyperinflation

Autor:innen und Institutionen

  • Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
  • Mayo Clinic Florida, Jacksonville, Florida.
  • University of Texas Southwestern Medical Center, Dallas, Texas.
  • University of Maryland Medical Center, Baltimore, Maryland.
  • Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Gerard J Criner, Ravi Kalhan

Förderung

  • Olympus Corporation

Zitieren

APA

Criner, G. J., Mallea, J. M., Abu-Hijleh, M., Sachdeva, A., Kalhan, R., Hergott, C. A., Lazarus, D. R., Mularski, R. A., Calero, K., Reed, M. F., Nsiah-Dosu, S., Himes, D., Kubo, H., Kinsey, C. M., Majid, A., Hogarth, D. K., Kaplan, P. V., Case, A. H., Makani, S. S., …, & Shepherd, R. W. (2024). Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.202306-520oc

Vancouver

Criner GJ, Mallea JM, Abu-Hijleh M, Sachdeva A, Kalhan R, Hergott CA, et al. Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE. Annals of the American Thoracic Society. 2024. doi:10.1513/annalsats.202306-520oc

BibTeX
@article{Criner2024,
  author = {Criner, Gerard J and Mallea, Jorge M and Abu-Hijleh, Muhanned and Sachdeva, Ashutosh and Kalhan, Ravi and Hergott, Christopher A and Lazarus, Donald R and Mularski, Richard A and Calero, Karel and Reed, Michael F and Nsiah-Dosu, Stephanie and Himes, David and Kubo, Hiroshi and Kinsey, C Matthew and Majid, Adnan and Hogarth, D Kyle and Kaplan, Philip V and Case, Amy Hajari and Makani, Samir S and Chen, Tze-Ming and Delage, Antoine and Zgoda, Michael and Shepherd, Ray W},
  title = {Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE},
  journal = {Annals of the American Thoracic Society},
  year = {2024},
  doi = {10.1513/annalsats.202306-520oc}
}
Kostenlos starten →